Chia-Kuan Peng

Title: Innovations of Chia-Kuan Peng in Hepatitis B Therapeutic Vaccines

Introduction

Chia-Kuan Peng is a notable inventor based in Hsinchu County, Taiwan. He has made significant contributions to the field of medical research, particularly in the development of therapeutic vaccines for hepatitis B. His innovative work has the potential to impact public health positively.

Latest Patents

Chia-Kuan Peng holds a patent for a fusion protein designed for use as a hepatitis B therapeutic vaccine. This fusion protein comprises an antigen-presenting cell (APC)-binding domain or a CD91 receptor-binding domain, a protein transduction domain, and an antigen that includes a hepatitis B virus X protein deletion mutant. The protein transduction domain is a fusion polypeptide that consists of a T cell sensitizing signal-transducing peptide, a linker, and a translocation peptide. The APC-binding domain or the CD91 receptor-binding domain is positioned at the N-terminus of the fusion protein, while the antigen is located at the C-terminus of the protein transduction domain. This innovative approach aims to enhance the efficacy of hepatitis B vaccines.

Career Highlights

Chia-Kuan Peng is associated with Thevax Genetics Vaccine Co., Ltd., where he continues to advance his research in vaccine development. His work is characterized by a commitment to improving therapeutic options for hepatitis B, showcasing his dedication to medical innovation.

Collaborations

Chia-Kuan Peng collaborates with esteemed colleagues, including Chia-Mao Wu and Jiun-Ming Wu. These partnerships enhance the research and development efforts within the field of vaccine technology.

Conclusion

Chia-Kuan Peng's contributions to hepatitis B therapeutic vaccines exemplify the importance of innovation in medical research. His work not only advances scientific knowledge but also holds promise for improving health outcomes for individuals affected by hepatitis B.